MAP3K2(MEKK2)
Sign in to save this workspaceUniProt Q9Y2U5 · PDB · AlphaFold · Substrate: MBP · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ponatinib | 88.3% | 11.7% | 78.23 | 0.534 |
| 2 | Crizotinib | 83.7% | 16.3% | 91.39 | 0.581 |
| 3 | Repotrectinib | 80.1% | 19.9% | 84.21 | 0.608 |
| 4 | Nintedanib | 76.9% | 23.1% | 90.23 | 0.608 |
| 5 | Ripretinib | 69.3% | 30.7% | 92.95 | 0.674 |
| 6 | Pemigatinib | 67.2% | 32.8% | 98.23 | 0.718 |
| 7 | Neratinib | 59.2% | 40.8% | 93.18 | 0.597 |
| 8 | Bosutinib | 58.4% | 41.6% | 87.22 | 0.555 |
| 9 | Ruxolitinib | 52.6% | 47.4% | 98.25 | 0.592 |
| 10 | Infigratinib | 48.9% | 51.1% | 98.24 | 0.710 |
| 11 | Sunitinib | 46.8% | 53.2% | 91.73 | 0.524 |
| 12 | Midostaurin | 43.5% | 56.5% | 78.64 | 0.500 |
| 13 | Baricitinib | 39.4% | 60.6% | 97.99 | 0.616 |
| 14 | Pacritinib | 39.3% | 60.7% | 88.64 | 0.452 |
| 15 | Apatinib | 38.2% | 61.8% | 97.73 | 0.704 |
| 16 | Defactinib | 22.5% | 77.5% | 92.68 | 0.450 |
| 17 | Erdafitinib | 16.9% | 83.1% | 95.71 | 0.737 |
| 18 | Lazertinib | 16.7% | 83.3% | 97.47 | 0.674 |
| 19 | Capivasertib | 16.4% | 83.6% | 96.48 | 0.644 |
| 20 | Gilteritinib | 14.7% | 85.3% | 88.97 | 0.506 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.20
- Epithelial log2(TPM+1): 2.80
- Fold change: 0.41
- Status: No significant change
Selectivity landscape vs inhibition on MAP3K2
Each point is one of the 92 approved drugs; color = inhibition % on MAP3K2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…